Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

JTO Clinical and Research Reports（2021）

引用 5|浏览38

暂无评分

摘要

Clinically meaningful efficacy was observed with RAM + ERL versus PL + ERL in the RELAY Japanese subset, with no new safety concerns. Postprogression T790M rates were similar across treatment arms, indicating the addition of RAM did not affect the ERL-associated T790M rates at disease progression

查看译文

关键词

Circulating tumor DNA,EGFR,Non–small cell lung cancer,Japan,Ramucirumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要